Allogene gains 17 assets from Pfizer
Newly launched with $300mm in Series A backing, Allogene Therapeutics Inc. is acquiring from Pfizer Inc. assets that the Big Pharma licensed from Cellectis SA in 2014 and Servier SA in 2015.
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.